MX2013013655A - Hipertension e hiperuricemia. - Google Patents
Hipertension e hiperuricemia.Info
- Publication number
- MX2013013655A MX2013013655A MX2013013655A MX2013013655A MX2013013655A MX 2013013655 A MX2013013655 A MX 2013013655A MX 2013013655 A MX2013013655 A MX 2013013655A MX 2013013655 A MX2013013655 A MX 2013013655A MX 2013013655 A MX2013013655 A MX 2013013655A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- serum uric
- uric acid
- acid levels
- oat4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
- C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
- C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un método para el tratamiento de la hipertensión en un sujeto que lo necesite (en el que, por ejemplo, dicho tratamiento no produzca aumento en los niveles de ácido úrico en suero, niveles anormalmente elevados de ácido úrico en suero, hiperuricemia, niveles de ácido úrico en suero superiores a 6 mg/1, o el desarrollo de gota en el sujeto), comprendiendo el método administrar al sujeto: a. un diurético de tiazida; y b. un inhibidor del transportador 4 de aniones orgánicos (OAT4). El diurético de tiazida se selecciona de hidroclorotiazida, bendroflumetiazida, benzotiadiazina, hidroflumetiazida, clorotiazida, meticlotiazida, politiazida, clortalidona, metolazona, indapamida, bumetanida, ácido etacrínico, furosemida o torsemida. El inhibidor de OAT4 es ácido 2-(5-bromo-4-(4-ciclopr opilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio) acético o una sal del mismo farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489597P | 2011-05-24 | 2011-05-24 | |
| PCT/US2012/039011 WO2012162323A1 (en) | 2011-05-24 | 2012-05-22 | Hypertension and hyperuricemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013655A true MX2013013655A (es) | 2014-08-21 |
| MX348281B MX348281B (es) | 2017-06-02 |
Family
ID=47217678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013655A MX348281B (es) | 2011-05-24 | 2012-05-22 | Hipertension e hiperuricemia. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20140171424A1 (es) |
| EP (1) | EP2714669B1 (es) |
| JP (1) | JP5964952B2 (es) |
| KR (1) | KR101624023B1 (es) |
| CN (1) | CN103702986A (es) |
| AU (1) | AU2012258860B2 (es) |
| BR (1) | BR112013030078A2 (es) |
| CA (1) | CA2837080C (es) |
| CY (1) | CY1119156T1 (es) |
| DK (1) | DK2714669T3 (es) |
| EA (1) | EA201370247A1 (es) |
| ES (1) | ES2633762T3 (es) |
| HR (1) | HRP20171054T1 (es) |
| HU (1) | HUE033868T2 (es) |
| IL (1) | IL229537A0 (es) |
| LT (1) | LT2714669T (es) |
| MX (1) | MX348281B (es) |
| MY (1) | MY163930A (es) |
| NZ (1) | NZ618373A (es) |
| PL (1) | PL2714669T3 (es) |
| PT (1) | PT2714669T (es) |
| RS (1) | RS56225B1 (es) |
| SG (1) | SG195112A1 (es) |
| SI (1) | SI2714669T1 (es) |
| UA (1) | UA109943C2 (es) |
| WO (1) | WO2012162323A1 (es) |
| ZA (1) | ZA201308807B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2217577T3 (da) | 2007-11-27 | 2014-10-20 | Ardea Biosciences Inc | Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf |
| US9402827B2 (en) | 2010-03-30 | 2016-08-02 | Ardea Biosciences, Inc. | Treatment of gout |
| PL2582683T3 (pl) | 2010-06-15 | 2018-08-31 | Ardea Biosciences, Inc. | Leczenie dny moczanowej i hiperurykemii |
| CN104311452B (zh) * | 2014-09-27 | 2016-01-06 | 张远强 | 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途 |
| CN104292124B (zh) * | 2014-09-27 | 2016-01-20 | 张远强 | 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途 |
| KR102487604B1 (ko) * | 2020-11-06 | 2023-01-12 | 에스케이케미칼 주식회사 | 히드로플루메티아지드를 유효성분으로 포함하는 TNF-α 관련 질환 예방 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
| US20090054319A1 (en) * | 2005-03-17 | 2009-02-26 | Microbia, Inc. | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders |
| DK2217577T3 (da) * | 2007-11-27 | 2014-10-20 | Ardea Biosciences Inc | Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf |
| US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| JP2012502050A (ja) * | 2008-09-04 | 2012-01-26 | アルディア バイオサイエンス，インク． | 尿酸値を調節するための化合物、組成物及びそれを使用する方法。 |
-
2012
- 2012-05-22 AU AU2012258860A patent/AU2012258860B2/en not_active Ceased
- 2012-05-22 PT PT127892685T patent/PT2714669T/pt unknown
- 2012-05-22 SG SG2013086574A patent/SG195112A1/en unknown
- 2012-05-22 MX MX2013013655A patent/MX348281B/es active IP Right Grant
- 2012-05-22 CN CN201280036513.7A patent/CN103702986A/zh active Pending
- 2012-05-22 US US14/119,599 patent/US20140171424A1/en not_active Abandoned
- 2012-05-22 CA CA2837080A patent/CA2837080C/en not_active Expired - Fee Related
- 2012-05-22 HU HUE12789268A patent/HUE033868T2/en unknown
- 2012-05-22 DK DK12789268.5T patent/DK2714669T3/en active
- 2012-05-22 NZ NZ618373A patent/NZ618373A/en not_active IP Right Cessation
- 2012-05-22 ES ES12789268.5T patent/ES2633762T3/es active Active
- 2012-05-22 UA UAA201315150A patent/UA109943C2/uk unknown
- 2012-05-22 RS RS20170696A patent/RS56225B1/sr unknown
- 2012-05-22 EP EP12789268.5A patent/EP2714669B1/en active Active
- 2012-05-22 EA EA201370247A patent/EA201370247A1/ru unknown
- 2012-05-22 JP JP2014512951A patent/JP5964952B2/ja not_active Expired - Fee Related
- 2012-05-22 PL PL12789268T patent/PL2714669T3/pl unknown
- 2012-05-22 SI SI201231005T patent/SI2714669T1/sl unknown
- 2012-05-22 BR BR112013030078A patent/BR112013030078A2/pt not_active Application Discontinuation
- 2012-05-22 KR KR1020137034028A patent/KR101624023B1/ko active IP Right Grant
- 2012-05-22 WO PCT/US2012/039011 patent/WO2012162323A1/en active Application Filing
- 2012-05-22 LT LTEP12789268.5T patent/LT2714669T/lt unknown
- 2012-05-22 MY MYPI2013004222A patent/MY163930A/en unknown
-
2013
- 2013-11-21 IL IL229537A patent/IL229537A0/en unknown
- 2013-11-22 ZA ZA2013/08807A patent/ZA201308807B/en unknown
-
2017
- 2017-07-11 HR HRP20171054TT patent/HRP20171054T1/hr unknown
- 2017-07-18 CY CY20171100766T patent/CY1119156T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1119156T1 (el) | 2018-02-14 |
| HRP20171054T1 (hr) | 2017-10-06 |
| BR112013030078A2 (pt) | 2016-08-09 |
| AU2012258860B2 (en) | 2015-12-03 |
| SG195112A1 (en) | 2013-12-30 |
| CA2837080C (en) | 2017-01-24 |
| EP2714669A1 (en) | 2014-04-09 |
| KR20140023396A (ko) | 2014-02-26 |
| CN103702986A (zh) | 2014-04-02 |
| IL229537A0 (en) | 2014-01-30 |
| RS56225B1 (sr) | 2017-11-30 |
| EA201370247A1 (ru) | 2014-07-30 |
| LT2714669T (lt) | 2017-08-10 |
| UA109943C2 (xx) | 2015-10-26 |
| JP2014515376A (ja) | 2014-06-30 |
| KR101624023B1 (ko) | 2016-05-24 |
| MX348281B (es) | 2017-06-02 |
| EP2714669A4 (en) | 2015-01-07 |
| PT2714669T (pt) | 2017-07-21 |
| US20140171424A1 (en) | 2014-06-19 |
| HUE033868T2 (en) | 2018-01-29 |
| EP2714669B1 (en) | 2017-04-26 |
| MY163930A (en) | 2017-11-15 |
| CA2837080A1 (en) | 2012-11-29 |
| AU2012258860A1 (en) | 2014-01-09 |
| WO2012162323A1 (en) | 2012-11-29 |
| ES2633762T3 (es) | 2017-09-25 |
| JP5964952B2 (ja) | 2016-08-03 |
| ZA201308807B (en) | 2019-07-31 |
| PL2714669T3 (pl) | 2017-09-29 |
| NZ618373A (en) | 2015-10-30 |
| SI2714669T1 (sl) | 2017-10-30 |
| DK2714669T3 (en) | 2017-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG195112A1 (en) | Hypertension and hyperuricemia | |
| Johnston et al. | Alternative systems for misfolded protein clearance: life beyond the proteasome | |
| Samarasinghe et al. | Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux | |
| Arigo et al. | Regulation of yeast NRD1 expression by premature transcription termination | |
| Theodoraki et al. | A network of ubiquitin ligases is important for the dynamics of misfolded protein aggregates in yeast | |
| Tan et al. | TLS inhibits RNA polymerase III transcription | |
| Chaumont et al. | Acute kidney injury in elderly patients with chronic kidney disease: Do angiotensin‐converting enzyme inhibitors carry a risk? | |
| CA2915566C (en) | 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors | |
| US20240009201A1 (en) | Cyp11b2 beta hydroxylase inhibitors for hypertension | |
| WO2020232125A1 (en) | Tl1a patient selection methods, systems, and devices | |
| JP2014515376A5 (es) | ||
| Singh et al. | Recent advances in antifungal drug development targeting lanosterol 14α‐demethylase (CYP51): a comprehensive review with structural and molecular insights | |
| Devasia et al. | Azole-based antibacterial agents: A review on multistep synthesis strategies and biology | |
| Ye et al. | TNNC1 reduced gemcitabine sensitivity of nonsmall-cell lung cancer by increasing autophagy | |
| WO2019209942A1 (en) | Methods and systems for characterizing severe crohn's disease | |
| Polzin et al. | Management of glomerulopathies | |
| Chia et al. | Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir. | |
| Futrakul et al. | Vascular response to vasodilator treatment in microalbuminuric diabetic kidney disease | |
| Cha | Mineralocorticoid receptor blockade for renoprotection | |
| Ikoma et al. | Bilateral aldosteronoma associated with secondary aldosteronism in a chronic hemodialysis subject | |
| WO2022026851A1 (en) | Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna | |
| CA3105464A1 (en) | Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures | |
| Mitsumori | Cytomegalovirus antigenaemia: 3 case reports | |
| Efthimia | Deferasirox/deferiprone | |
| Naithani | Tumour lysis syndrome and acute renal failure: case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |